HOME
CAREERS
CONTACT US
KOREAN
ENGLISH
KR
EN
Toggle navigation
COMPANY
ABOUT US
KEY MEMBERS
HISTORY
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
SCIENCE
NT-I7
NeoBase
NT2020
NT3020
NT4010
NT5010
PIPELINE
Clinical
R&D
COLLABORATION
INVESTORS
NOTICE
PRESENTATION
GENERAL MEETING
OF STOCKHOLDERS
INDEPENDENT
AUDITOR'S REPORT
CONTACT IR
MEDIA
NEWS
VIDEO SOURCE
ESG
OVERVIEW
ENVIRONMENTAL
SOCIAL
GOVERNANCE
NEWS
HOME
MEDIA
NEWS
NEWS
All
Press Release
News Update
Quarterly update
Total
83
53
Press Release
NeoImmuneTech to Present at Upcoming Business Conferences
2022-02-09
52
Press Release
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 checkpoint inhibitor in High-Risk Skin Cancers
2022-02-07
51
Press Release
Preclinical Data on NT-I7 Published in Clinical Cancer Research
2022-01-24
50
Press Release
NeoImmuneTech to Present at 2022 Biotech Showcase at J.P. Morgan Healthcare Conference
2022-01-05
49
Press Release
NeoImmuneTech Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting
2021-11-22
48
Press Release
NeoImmuneTech Presents Data in Three Posters at Society for Immunotherapy of Cancer Annual Meeting
2021-11-16
47
Press Release
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2021-11-08
46
Press Release
NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma
2021-10-13
45
Press Release
NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting
2021-10-05
44
Press Release
NeoImmuneTech to Present at Society for Neuro-Oncology Annual Meeting
2021-09-03
1
2
3
4
5
>
>>
Search